Abstract: Colorectal cancer (CRC) is frequently driven by mutations in the KRAS oncogene, a target historically deemed "undruggable." The discovery of the switch-II pocket in the KRAS G12C mutant variant has led to the development of direct, covalent inhibitors. Adagrasib (MRTX849) is a potent, mutant-specific inhibitor that irreversibly binds to the inactive GDP-bound state of KRAS G12C. While adagrasib monotherapy has demonstrated promising clinical activity in CRC, its efficacy is often limited by rapid upstream epidermal growth factor receptor (EGFR) reactivation and acquired resistance mechanisms. Consequently, combination strategies, particularly with the EGFR inhibitor cetuximab, have shown significantly improved objective response rates and disease control, leading to FDA approval for this combination in advanced KRAS G12C-mutated CRC. This review summarizes the pharmacological activity, molecular mechanism, structure-activity relationship, current limitations, and future perspectives of adagrasib in the treatment of colorectal cancer.
1. Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide, and activating mutations in the KRAS oncogene are among the most frequent genetic aberrations, occurring in approximately 40% of CRC cases [4]. For decades, KRAS was considered an "undruggable" target due to its exceptionally high affinity for cellular guanosine triphosphate (GTP) and the absence of deep hydrophobic pockets suitable for small-molecule binding [1]. However, a paradigm shift occurred with the identification of a cryptic allosteric pocket (the switch-II pocket) in the KRAS G12C mutant variant [4]. Although the KRAS G12C mutation accounts for only a minor subset (approximately 3% to 4%) of metastatic CRCs, it identifies a patient population with aggressive disease biology and poor survival outcomes [1][8]. Adagrasib (MRTX849) emerged as a first-in-class, highly selective, and irreversible covalent inhibitor specifically designed to target the KRAS G12C mutation, marking a significant breakthrough in precision oncology for CRC [1][8].
2. Pharmacological Activity
Adagrasib has demonstrated robust pharmacological activity in both preclinical models and clinical trials. In the phase I/II KRYSTAL-1 trial, adagrasib was evaluated in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors [8]. As a monotherapy in CRC, adagrasib yielded an objective response rate (ORR) ranging from 17% to 22% and a high disease control rate (DCR) between 86% and 94% [1][4][8]. The median progression-free survival (mPFS) for monotherapy was reported at 5.6 months, with a median overall survival (mOS) of 19.8 months [8].
Notably, CRC exhibits a distinct biological response to KRAS inhibition compared to non-small cell lung cancer (NSCLC). In CRC, the inhibition of the MAPK pathway downstream of KRAS leads to a rapid feedback reactivation of the upstream EGFR pathway, which blunts the efficacy of KRAS monotherapy [1][8][12]. To overcome this adaptive resistance, adagrasib was combined with the EGFR inhibitor cetuximab. This dual blockade significantly enhanced clinical efficacy, achieving an ORR of 34% to 46%, a DCR of up to 100%, and an mPFS of 6.9 months [1][8][15]. Based on these favorable outcomes, the FDA approved the adagrasib and cetuximab combination regimen for patients with advanced CRC harboring the KRAS G12C mutation [15]. Pharmacokinetically, adagrasib possesses a long half-life of approximately 24.7 hours, allowing for sustained target inhibition and a twice-daily oral dosing regimen [7][14].
3. Molecular Mechanism of Action
The oncogenic KRAS G12C mutation impairs GTPase-activating protein (GAP)-mediated hydrolysis, leading to an accumulation of the active, GTP-bound state of the KRAS protein, which continuously drives cellular proliferation [4]. However, unlike other KRAS mutations, the G12C variant preserves a near-wild-type intrinsic GTPase activity, allowing it to maintain a slight GTP-to-GDP cycling ability [4][17]. Adagrasib exploits this biochemical vulnerability by selectively binding to the KRAS G12C protein only when it is in its inactive, GDP-bound conformation [12][19]. By covalently attaching to the mutant protein, adagrasib irreversibly locks KRAS G12C in this inactive state. This prevents the nucleotide exchange required for KRAS activation, thereby blocking its interaction with downstream effectors and effectively shutting down the RAF/MEK/ERK (MAPK) signaling cascade [6][19].
4. Structure-Activity Relationship (SAR)
The development of adagrasib was driven by meticulous structure-based drug design, optimizing precursor molecules (such as MRTX1257) to enhance both potency and pharmacokinetic properties [7]. Adagrasib targets the cryptic "switch-II pocket" of the KRAS G12C protein. The core mechanism of its selectivity and irreversible action is the formation of a covalent bond with the reactive thiol group of the mutant cysteine 12 residue [4][19].
Furthermore, the binding affinity of adagrasib is significantly enhanced by its precise spatial engagement with the H95/Y96/Q99 residues within the cryptic pocket. Specifically, adagrasib forms a critical hydrogen bond between the hydroxyl group of the tyrosine 96 (Y96) residue and its own pyrimidine ring [12]. This precise structural interaction ensures high selectivity for the G12C mutant over wild-type KRAS and other variants, minimizing off-target toxicity while maximizing target occupancy [6][13].
5. Current Limitations
Despite its clinical success, the efficacy of adagrasib is constrained by primary and acquired resistance, as well as drug-related toxicities. In CRC, primary resistance is frequently mediated by the rapid feedback activation of upstream receptor tyrosine kinases (RTKs), particularly EGFR, which bypasses KRAS inhibition and necessitates combination therapies [8][12].
Acquired resistance inevitably develops in most responders and is highly heterogeneous. On-target resistance mechanisms include secondary mutations within the drug-binding pocket (e.g., Y96C, R68S, H95D/Q/R) and other activating KRAS mutations (e.g., G12D/R/V/W, G13D, Q61H) or KRAS amplification [5][8]. The Y96 mutation is particularly problematic as it disrupts the critical hydrogen bond required for adagrasib binding, conferring strong cross-resistance [5][12]. Off-target (bypass) resistance mechanisms involve the activation of parallel signaling pathways, including MET amplification, activating mutations in BRAF, NRAS, MAP2K1, and PIK3CA, as well as oncogenic gene fusions involving ALK, RET, and FGFR3 [2][5][8].
Clinically, adagrasib is associated with treatment-related adverse events (TRAEs), predominantly gastrointestinal and hepatic toxicities. Common adverse effects include diarrhea, nausea, vomiting, fatigue, and elevated alanine/aspartate aminotransferase (ALT/AST) levels, which can lead to dose reductions or treatment interruptions [5][10][14].
6. Future Perspectives
To overcome the limitations of adagrasib monotherapy, future strategies are heavily focused on rational combination therapies. The success of combining adagrasib with cetuximab in CRC highlights the importance of vertical pathway inhibition [8]. Ongoing clinical trials are evaluating adagrasib in combination with other targeted agents, such as SHP2 inhibitors (e.g., TNO155), SOS1 inhibitors (e.g., BI 1701963), and PI3K/AKT/mTOR pathway inhibitors, to prevent adaptive resistance and achieve deeper tumor regression [2][4][8].
Additionally, the immunomodulatory potential of KRAS inhibitors provides a strong rationale for combining adagrasib with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies), which is currently under investigation [1][8]. To address secondary resistance mutations like Y96C, next-generation KRAS inhibitors are being developed. These include tri-complex inhibitors that target the active GTP-bound (ON) state of KRAS, as well as novel therapeutic modalities like PROTAC-mediated protein degradation and mRNA-based cancer vaccines [4][5][13][14]. These advancements hold the promise of extending the durability of response and expanding the treatable patient population in KRAS-mutated CRC.
